# New drug candidate developed to treat type 2 diabetes

August 26 2022, by Birgit Niesing

GLP-1RA/tesaglitazar in obese GLP-1R knockout mice. a–n, Body weight (a,h), change in fat and lean tissue mass (b,c,i,j), cumulative food intake (d,k), blood glucose (e,l) and i.p. GTT (f,m) in 36-week-old male DIO wildtype (WT) (a–g) or GLP-1R knockout (KO) mice (h–n) treated for 6 days with either vehicle or 50 nmol kg^{-1} per day of GLP-1RA/tesaglitazar. Sample sizes for treatment with Vhcl or GLP-1RA/tesaglitazar are n = 8/8 (a–c,e,f), n = 8/7 (g) and n = 7/7 (h–j,l–n). Cumulative food intake was assessed per cage in n = 4/3 cages containing n = 8/8 mice (d) and n = 4/5 cages containing n = 7/7 mice (k). Data in a, d, f, h, k and m have been analyzed by two-way ANOVA with Bonferroni post hoc comparison for individual time points. Data in b, c, e, g, i, j, l and n have been analyzed by one-way ANOVA using Bonferroni's multiple comparison test. Data represent means ± s.e.m.; asterisks indicate *P

Citation: New drug candidate developed to treat type 2 diabetes (2022, August 26) retrieved 23

April 2024 from https://medicalxpress.com/news/2022-08-drug-candidate-diabetes.html